推薦產品
等級
pharmaceutical primary standard
API 家族
venlafaxine
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
Cl[H].COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2
InChI
1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H
InChI 密鑰
QYRYFNHXARDNFZ-UHFFFAOYSA-N
基因資訊
human ... SLC6A2(6530) , SLC6A4(6532)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Venlafaxine hydrochloride USP reference standard intended for use in specified quality tests and assays.
Also used to prepare standard, system suitability, and standard stock solution for assay, impurity analysis, and performance test according to the given below monographs of United States Pharmacopeia (USP):
Also used to prepare standard, system suitability, and standard stock solution for assay, impurity analysis, and performance test according to the given below monographs of United States Pharmacopeia (USP):
- Venlafaxine Hydrochloride
- Venlafaxine Tablets
- Venlafaxine Hydrochloride Extended-Release Capsules
- Desvenlafaxine
生化／生理作用
文拉法辛是一种 5-羟色胺-去甲肾上腺素再摄取抑制剂，其 Ki 值分别为 82 和 2480 nM。它是一种普通的抗抑郁药。
文拉法辛是抗抑郁药。文拉法辛在人中的抗抑郁作用机制与其在中枢神经系统中神经递质活性的增强有关。文拉法辛是神经元 5-羟色胺和去甲肾上腺素再摄取的有效抑制剂，是多巴胺再摄取的弱抑制剂。在体外，文拉法辛对毒蕈碱、组胺能或 α-1 肾上腺素能受体无明显活性。文拉法辛不具有 MAO 抑制剂活性。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
危險聲明
危險分類
Aquatic Chronic 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Desvenlafaxine
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(5), 1280-1280 (2020)
R L Rudolph et al.
Journal of clinical psychopharmacology, 16(3 Suppl 2), 54S-59S (1996-06-01)
The tolerability and safety of venlafaxine hydrochloride, a new serotonin and norepinephrine reuptake inhibitor, are reviewed in this article. The data presented here are based on a pool of 3,082 patients who were treated with this agent during clinical trials.
Denise G Tate et al.
Archives of physical medicine and rehabilitation, 96(2), 340-348 (2014-12-03)
To assess the role that treatment response plays in a randomized controlled trial of an antidepressant among people with spinal cord injury (SCI) diagnosed with major depressive disorder (MDD) in explaining quality of life (QOL), assessed both globally as life
Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
Florence Gressier et al.
The American journal of psychiatry, 171(8), 890-890 (2014-08-02)
C Reichert et al.
Clinical toxicology (Philadelphia, Pa.), 52(6), 629-634 (2014-05-23)
Seizures during intoxications with pharmaceuticals are a well-known complication. However, only a few studies report on drugs commonly involved and calculate the seizure potential of these drugs. To identify the pharmaceutical drugs most commonly associated with seizures after single-agent overdose
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務